[1]
J. Beca, H. Majeed, K. K. Chan, S. J. Hotte, A. Loblaw, and J. S. Hoch, “Cost-effectiveness of docetaxel in high-volume hormone-sensitive metastatic prostate cancer”, CUAJ, vol. 13, no. 12, pp. 396-403, Apr. 2019.